EGFR and cancer: The experts therefore also considered alternative testing strategies, such as serial monitoring using a small targeted panel or ddPCR for single markers such as mutations in B-Rapidly Accelerated Sarcoma (BRAF), EGFR or PIK3CA. A clinically feasible and economically viable approach may be to implement NGS as a first pass and then follow cancer progression using ddPCR, costing only USD 300 per test.